Fri, Aug 2, 12:09 PM (174 days ago)
Inspire Medical Systems, Inc. announced on August 2, 2024, that it received FDA approval for its Inspire V therapy system, which includes a next-generation neurostimulator, a Bluetooth® patient remote, and a physician programmer. This development is significant for the company's product portfolio and could positively impact its market position and stock value. The announcement was formalized through a press release attached as Exhibit 99.1 to the Form 8-K filing. The information provided in the Form 8-K is not considered "filed" for legal purposes and is not subject to Section 18 of the Securities Exchange Act of 1934 liabilities.